Disease · MONDO_0019471

adult T-cell leukemia/lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. adult T-cell leukemia/lymphoma. Diseases, record MONDO_0019471. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019471

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: adult T-cell leukemia/lymphoma; Open Targets
Open Targets ID: MONDO_0019471; Open Targets
Other names: ATLL, T-cell leukaemia of adults, T-cell leukemia of adults, adult T-cell leukaemia, adult T-cell leukemia; Open Targets
Disease Ontology: DOID:0050523; Disease Ontology
NCI Thesaurus: C3184; NCI Thesaurus
Orphanet: ORPHA:86875; Orphanet
Highest stage of its drugs: Approval, for 2 of its 50 drugs, from PMDA; Open Targets

Drugs50

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MOGAMULIZUMAB	CHEMBL1743041	Antibody	Approval	PMDA	8	7	7	Drugs and targets
VALEMETOSTAT TOSYLATE	CHEMBL4594405	Small molecule	Approval	PMDA	3	2	2	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	9	9	9	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ZIDOVUDINE	CHEMBL129	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ALEMTUZUMAB	CHEMBL1201587	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 50

See all 50 drugs

Targets109

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HDAC1	Histone deacetylase	3	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC10	Histone deacetylase	3	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/83933	Drugs and targets
HDAC11	Histone deacetylase	3	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/79885	Drugs and targets
HDAC2	Histone deacetylase	3	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	3	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC4	Histone deacetylase	3	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/9759	Drugs and targets
HDAC5	Histone deacetylase	3	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/10014	Drugs and targets
HDAC6	Histone deacetylase	3	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/10013	Drugs and targets
HDAC7	Histone deacetylase	3	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/51564	Drugs and targets
HDAC8	Histone deacetylase	3	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/55869	Drugs and targets

1 to 10 of 109

See all 109 targets

Trials38

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04703192	Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)	Phase 2	155	2024-07-22	Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma	VALEMETOSTAT TOSYLATE	Its record names the disease	ClinicalTrials.gov
NCT00001575	Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia	Phase 1/2	87	2015-12-07	Hodgkin's Disease, Lymphoma, Non-Hodgkin	PENTETATE CALCIUM TRISODIUM, YTTRIUM Y-90	Its record names the disease	ClinicalTrials.gov
NCT01626664	KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	Phase 2	71	2018-06-15	Adult T-cell Leukemia-Lymphoma	MOGAMULIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00001941	Anti-Tac for Treatment of Leukemia	Phase 1/2	34	2012-08-09	HTLV-I Infection, T Cell Leukemia	DACLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00061048	Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma	Phase 2	29	2011-06-08	Acute T-Cell Leukemia-Lymphoma	ALEMTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00920790	Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma	Phase 2	28	2012-09-25	Adult T-cell Leukemia-lymphoma	MOGAMULIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01724177	A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma	Phase 2	26	2016-01-05	Adult T-Cell Leukemia-Lymphoma	LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT02955589	Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)	Phase 2	23	2024-09-19	Adult T-Cell Lymphoma (ATL)	TUCIDINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT01712659	Ruxolitinib for Adult T-Cell Leukemia	Phase 1/2	19	2023-01-10	T Cell Leukemia, Adult, Leukemia, Adult T-Cell, T Cell Leukemia, HTLV I Associated	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT00924170	Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia	Phase 1/2	18	2017-09-08	Adult T-Cell Leukemia (ATL)	CYCLOPHOSPHAMIDE, FLUDARABINE, LMB-2	Its record names the disease	ClinicalTrials.gov

1 to 10 of 38

See all 38 trials

Comparisons in its trials11

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) vs Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma: deaths from any cause	52 of 133	16 of 22	155	NCT04703192	Trial comparisons
Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) vs Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma: serious adverse events	53 of 133	15 of 22	155	NCT04703192	Trial comparisons
Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC vs All Other Patients: Number of Participants With Dose Limiting Toxicity (DLT)	0 of 10	0 of 8	18	NCT00924170	Trial comparisons
Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC vs All Other Patients: Number of Participants With Serious and Non-serious Adverse Events	10 of 10	8 of 8	18	NCT00924170	Trial comparisons
Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC vs All Other Patients: deaths from any cause	8 of 10	6 of 8	18	NCT00924170	Trial comparisons
Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC vs All Other Patients: serious adverse events	7 of 10	6 of 8	18	NCT00924170	Trial comparisons
Cohort 1 vs Cohort 2: deaths from any cause	0 of 7	0 of 1	8	NCT04362007	Trial comparisons
Cohort 1 vs Cohort 2: serious adverse events	0 of 7	0 of 1	8	NCT04362007	Trial comparisons
Dose Level 1 (Interleukin-15 2mcg/kg/Day) vs Dose Level 2 (Interleukin-15 4mcg/kg/Day): Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	3 of 3	3 of 3	6	NCT04185220	Trial comparisons
Dose Level 1 (Interleukin-15 2mcg/kg/Day) vs Dose Level 2 (Interleukin-15 4mcg/kg/Day): deaths from any cause	2 of 3	1 of 3	6	NCT04185220	Trial comparisons

1 to 10 of 11

See all 11 comparisons in its trials

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35579212	RESULT	1	PubMed
27621400	RESULT	1	PubMed
22312108	RESULT	1	PubMed
19204798	RESULT	1	PubMed
40546724	DERIVED	1	PubMed
39486433	DERIVED	1	PubMed
36828681	DERIVED	1	PubMed
36150143	DERIVED	1	PubMed
35687761	DERIVED	1	PubMed
35475910	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019471

GET https://conductscience.org/api/diseases/v1/MONDO_0019471/drugs?page=2

API reference For AI assistants